anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuroinflammation is critically involved in nerve injury-induced neuropathic pain, characterized by local and systemic increased levels of proinflammatory cytokines. Interleukin-24 (IL-24), a key member of the IL-10 family, has been extensively studied for its therapeutic potential in various diseases, including cancer, autoimmune disorders, and bacterial infections, but whether it is involved in the regulation of neuropathic pain caused by peripheral nerve injury (PNI) has not been well established. In this study, we reported that spared nerve injury (SNI) induced a significant upregulation of IL-24 in fibroblasts, neurons, and oligodendrocyte precursor cells (OPCs, also called NG2-glia) in the affected spinal dorsal horns (SDHs), as well as dorsal root ganglions (DRGs). We also found that tumor necrosis factor α (TNF-α) induced the transcriptional expression of IL-24 in cultured fibroblasts, neurons, and NG2-glia; in addition, astrocytes, microglia, and NG2-glia treated with TNF-α exhibited a prominent increase in interleukin-20 receptor 2 (IL-20R2) expression. Furthermore, we evaluated the ability of IL-24 and IL-20R2 to attenuate pain in preclinical models of neuropathic pain. Intrathecal (i.t.) injection of IL-24 neutralizing antibody or IL-20R2 neutralizing antibody could effectively alleviate mechanical allodynia and thermal hyperalgesia after PNI. Similarly, intrathecal injection of IL-24 siRNA or IL-20R2 siRNA also alleviated mechanical allodynia after SNI. The inhibition of IL-24 reduced SNI-induced proinflammatory cytokine (IL-1β and TNF-α) production and increased anti-inflammatory cytokine (IL-10) production. Meanwhile, the inhibition of IL-20R2 also decreased IL-1β mRNA expression after SNI. Collectively, our findings revealed that IL-24/IL-20R might contribute to neuropathic pain through inflammatory response. Therefore, targeting IL-24 could be a promising strategy for treating neuropathic pain induced by PNI.
BACKGROUND: Preeclampsia, one of the most lethal pregnancy-related diseases, is associated with the disruption of uterine spiral artery remodeling during placentation. However, the early molecular events leading to preeclampsia remain unknown.
RESULTS: By analyzing placentas from preeclampsia, non-preeclampsia, and twin pregnancies with selective intrauterine growth restriction, we show that the pathogenesis of preeclampsia is attributed to immature trophoblast and maldeveloped endothelial cells. Delayed epigenetic reprogramming during early extraembryonic tissue development leads to generation of excessive immature trophoblast cells. We find reduction of de novo DNA methylation in these trophoblast cells results in selective overexpression of maternally imprinted genes, including the endoretrovirus-derived gene PEG10 (paternally expressed gene 10). PEG10 forms virus-like particles, which are transferred from the trophoblast to the closely proximate endothelial cells. In normal pregnancy, only a low amount of PEG10 is transferred to maternal cells; however, in preeclampsia, excessive PEG10 disrupts maternal vascular development by inhibiting TGF-beta signaling.
CONCLUSIONS: Our study reveals the intricate epigenetic mechanisms that regulate trans-generational genetic conflict and ultimately ensure proper maternal-fetal interface formation.
OBJECTIVE: Both chronic kidney disease and its main treatment, hemodialysis (HD), are associated with hematological abnormalities. However, little is known about how starting hemodialysis when already in end-stage renal disease (ESRD) affects hematological parameters. This study investigated the effect of HD on hematological and coagulation markers among ESRD patients.
METHODS: A retrospective study was carried out on 43 HD-ESRD patients from January to December 2022. The data were collected from Sabt Alalaya General Hospital in Belgarn, Saudi Arabia. Using GraphPad Prism, multiple unpaired t-tests were utilized to compare hematological and coagulation markers between the patients and healthy subjects.
RESULTS: The 43 HD-ESRD patients (46.5% male and 53.5% female) ranged in age from 20 to 89 years. The data obtained from our analysis unsurprisingly revealed significant variation in hematological parameters and coagulation patterns among HD-ESRD patients. Most notably, there were gradual and significant changes in platelet, MCV, MPV, and INR values during the assessment time.
CONCLUSION: This investigation verified the possible occurrence of macrocytosis and thrombotic conditions among patients with ESRD who undergo HD. It is recommended to closely observe patients undergoing this procedure, with a specific focus on platelet, MCV, MPV, and INR levels as potential indications.
Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
In one aspect, a computerized method includes the step of obtaining a set of eye data of a patient from a medical practitioner in a computer input form. The method includes the step of acquiring a set of dry eye patient data from a set of well-structured dry eye patient data samples, wherein each sample dry eye patient data comprises a plurality of features. The method includes the step of identifying the plurality of data features in the set of well-structured dry eye patient data samples. The method includes the step of implementing a data cleaning process on the set of well-structured dry eye patient data samples. The method includes the step of implementing a feature selection on the set of well-structured dry eye patient data samples, wherein the feature selection comprises selecting a subset of relevant features for machine-learning model construction. The method includes the step of providing a specified machine-learning (ML) model. The method includes the step of training the ML model with the set of well-structured dry eye patient data samples. The method includes the step of validating the ML model with the set of well-structured dry eye patient data samples. The method includes the step of providing the set of eye data of the patient to the trained and validated ML model. With the trained and validated ML model, the method includes the step of classifying the set of eye data of the patient as a dry eye category and a dry eye type.
Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
A motion detection component is operated to detect movement of the motion detection component. The movement detected by the motion detection component is recorded. A display is operated to provide a visual indication of an amount of the recorded movement. Electrical signals are communicated from the motion detection component through an electrical contact. The electrical signals are associated with the detected and recorded movement of the motion detection component. The motion detection component, the display, and the electrical contact are included within a band formed to secure to a part of a human body.
The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.
During Part 1, Period 1, participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 1, Period 2, participants will receive a dose of itraconazole orally once daily on the morning of Day 1 to Day 13. On the morning of Day 5, participants will be given a single dose of ALXN2080 co-administered with itraconazole.
Chemotherapy is a major contributor to cachexia, but studies often investigate male animals. Here, we investigated whether sex modifies the effects of chemotherapy on cachexia and BCAA metabolism. Ten-week-old CD2F1 male and female mice were treated with the chemotherapy drug cocktail folfiri (50 mg/kg 5-fluorouracil, 90 mg/kg leucovorin, and 24 mg/kg CPT11) (drug) or vehicle twice a week for 6 weeks. Insulin tolerance tests were conducted and BCAA levels and metabolism were measured in plasma and tissues. Drug treatment reduced body and skeletal muscle weights and anabolic signaling in both sexes, with females showing worsened outcomes (p < 0.05 for all). Drug treatment increased plasma BCAA only in males, but BCAA concentrations in the skeletal muscle of both sexes were decreased; this decrease was more profound in males (p = 0.0097). In addition, muscle expression of the BCAA transporter LAT1 was reduced; this reduction was more severe in females (p = 0.0264). In both sexes, the (inhibitory) phosphorylation of BCKD-E1αser293 was increased along with decreased BCKD activity. In the liver, drug treatment increased BCAA concentrations and LAT1 expression, but BCKD activity was suppressed in both sexes (p < 0.05 for all). Our results demonstrate that altered BCAA metabolism may contribute to chemotherapy-induced cachexia in a sex-dependent manner.
A system and method for detecting vascular contamination by surgical anesthetic using non-invasive IR spectrophotometry. One embodiment is a method for operating an instrument such as an enhanced pulse oximeter to monitor a patient receiving local anesthetic marked with dye that absorbs infrared light. Light is applied to and detected from tissue of the patient. A signal representative of the detected light is processed to derive patient oxygenation information. The detected light is also processed to derive information representative of the presence of the dye-marked anesthetic. The oxygenation information and the information representative of the presence of anesthetic are displayed. The oxygenation monitoring and display and the anesthetic monitoring and display can occur separately or concurrently. Fluorescing dyes and fluorescence detection approaches are used for anesthetic detection in some embodiments. Other embodiments apply a sequence of light pulses and correlate the applied light pulse sequence to the detected signal to identify the presence of the dye-marked anesthetic.
This trial comprises three studies. In the first two studies, women will be randomly assigned to receive either real or sham acupuncture therapy. Study 1 will include women with various forms of cancer. White blood cell counts will be used to assess the effects of acupuncture on participants' immune responses. Study 2 will include women with unspecified pelvic pain and endometriosis; a self-report pain scale will be used to assess the effects of acupuncture on participants' symptoms. Study 3 will evaluate the validity and reliability of diagnoses made by Chinese medicine practitioners. In this study, a group of Chinese medicine practitioners will diagnose the same group of patients; consistency of the diagnoses will be evaluated.
NEW MATERIAL:A polyphenol compound having the following characteristics. Appearance, brownish powder; melting point, 185-190 deg.C (decomposition); molecular weight, 20,400; elemental analysis, C 58.19, H 4.53, N 0.00, ash 1.33 (Na); peak of UV absorption spectrum, 280nm in methanol. USE:A carcinostatic agent. Useful as an excellent chemotherapeutic agent for cancer of warm-blooded animal such as man and domestic animals. PREPARATION:The dry powder of bark of the twig of Pterocarpus indicus willd is extracted by immersing in hydrated methanol for a night under stirring, filtered, extracted again with hydrated methanol for a night, and filtered. Both filtrates are joined together to obtain the extract liquid, which is concentrated under reduced pressure to remove methanol. The concentrated product is adsorbed with a column packed with Sephadex HL200, washed with water, and eluted with dioxane. The eluted active component is collected, concentrated under reduced pressure, and purifid to obtain the objective polyphenol compound.
All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will "friend" other participants to utilize these features.
This study employs an experimental design conducted on patients in the stroke unit of the hospital who are over 20 years old and have either ischemic or hemorrhagic stroke with stable vital signs post-stroke onset, limb muscle strength greater than 3 points, and good communication skills in Chinese and Taiwanese, or they can read Chinese. Eligible participants are divided into an experimental group and a control group. All participants receive standard stroke unit care, while the intervention group additionally undergoes a 3-day activity protocol. The primary outcomes are assessed at baseline and at 1, 4, and 12 weeks post-stroke. Finally, the study analyzes the effect of early intervention on improving the prognosis of stroke patients.

The data collected in this study, whether in paper form or electronically, will be documented on a computer. After completing the research report, any recordings and paper documents will be destroyed. Once the data is documented, identifiable patient information will be removed, and each record will be assigned a unique code, making individual data unidentifiable.
NEW MATERIAL:The peptide of formula I -III(R is H or Tyr). USE:Diagnosis of the infection with human leukemia virus, and diagnosis and research of mature T-cell leukemia, lymphoma, and relating diseases such as adult T-cell leukemia, cutaneous T-cell lymphoma, etc. An antigen can be produced by using each peptide as a hapten, and an antibody having specific reactivity with virus-relating protein can be obtained from the antigen. The specific antibody is bonded e.g. with a carrier for affinity chromatography, and used as a specific antibody for the purification of virus-relating protein or the immunoassay of virus-relating protein. PREPARATION:The objective peptide can be prepared either by condensing amino acids one by one to the terminal amino acid by conventional peptide synthesis (e.g. azide process, chloride process, DCC process, etc.) or by coupling several number of fragments constituting the peptide. If necessary, the side chain functional groups are protected before the reaction, and removed from the obtained reaction product.
Methylprednisolone Tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water.   
The chemical name for methylprednisolone is pregna-1, 4-diene-3, 20-dione, 11, 17, 21-trihydroxy-6-methyl-, (6α, 11β)-and the molecular weight is 374.48. The structural formula is represented below: 

Each Methylprednisolone tablet for oral administration contains 4mg of methylprednisolone.

Inactive ingredients: Colloidal Silicon Dioxide, Lactose Monohydrate-Cellulose Microcrystalline, Magnesium Stearate, Croscarmellose Sodium.
OBJECTIVE: The empty pelvis syndrome (EPS) is common after pelvic exenteration (PE), causing fluid collections, bowel obstruction, perineal sinuses, and fistulas. The best approach to fill the pelvis to mitigate this remains controversial, and the impact of EPS on health-related quality of life (HrQoL) is unknown. This study is the first to begin to explore lived-experiences of EPS complications.
METHODS: Unstructured EPS virtual focus group meetings were conducted with a convenience sample of patients who underwent PE, as an extension of a modified-Delphi study. Interpretative phenomenological analysis was conducted on verbatim transcripts to generate group experiential themes.
RESULTS: Twelve patients (eight UK, one Dutch, and three Belgian) participated in four focus groups. Eight EPS complications were reported, (two pelvic collections, five chronic perineal sinuses, and one bowel obstruction). Group experiential themes were 'Out of Options', depicting patients forced to accept complications or limited survival; 'The New Normal', with EPS potentially delaying adaptation to post-PE HrQoL; 'Information Influencing Adaptation,' emphasising the significance of patients understanding EPS to cope with its effects; and 'Symptoms,' reporting manifestations of EPS, the resultant physical limitations, and an intangible feeling that patients lost part of themselves.
CONCLUSIONS: EPS may influence patient decision-making, regret, adaptation, and information-seeking. It can cause a variety of unpleasant symptoms and physical limitations, which may include phantom phenomenon. This work supports ongoing purposeful HrQoL research to better define these themes.
The present disclosure provides an antimicrobial peptide (AMP) for controlling Pseudomonas syringae pv. actinidiae (PSA) and a preparation method and use thereof, belonging to the technical field of biological control. In the present disclosure, the AMP has an amino acid sequence of Trp-Trp-Lys-Leu-Leu-Arg-Lys-Leu-NH2, and has a typical amphiphilic structure. The AMP can target a cell membrane of the PSA, increasing permeabilization and dissipating a membrane potential, which leads to calcium ion leakage. The AMP also acts on intracellular targets, affects DNA functions, reduces an activity of esterases, and induces the generation of reactive oxygen species (ROS). The AMP has a minimal inhibitory concentration (MIC) of 3.13 μg/mL and a half maximal effective concentration (EC50) of 1.67 μg/mL for the PSA, showing an activity significantly higher than that of agricultural streptomycin.
Application of a topical anesthetic cream to the infusion site prior to administration of AMONDYS 45 may be considered. 

AMONDYS 45 is administered via intravenous infusion. Flush the intravenous access line with 0.9% Sodium Chloride Injection, USP, prior to and after infusion. 

Infuse the diluted AMONDYS 45 over 35 to 60 minutes via an in-line 0.2 micron filter. Do not mix other medication with AMONDYS 45 or infuse other medications concomitantly via the same intravenous access with AMONDYS 45. 

If a hypersensitivity reaction occurs, consider slowing the infusion, interrupting or discontinuing the AMONDYS 45 therapy [see Contraindications (4), Warning and Precautions (5.1) and Adverse Reactions (6.2)].
Embodiments can enable coordinated access to electronic medical records (EMRs) by mobile devices in communication with an EMR coordination server over a communications network, thereby integrating the EMR access into the physician's workflow. The EMR coordination server can receive a schedule request for a physician via the mobile device, and can identify appointments associated with the physician. Each appointment can be associated with a patient, an EMR server identified as having the patient's records, and a network location and EMR schema. The physician can select an appointment to access associated fields. The fields can be populated with fresh data from the identified EMR server, accessed by its network location, and mapped according to its EMR schema. Field data can be updated by physician dictation (or otherwise) and dictated audio can be automatically transcribed. Embodiments can operate even in context of multiple EMR servers having multiple EMR schemas and/or network locations.
A knitted sock has an inner layer (2) comprising a toe end (4) and an outer layer (3) comprising a toe end (7). The inner and outer toe ends are aligned and joined wale stitch to wale stitch to form a composite to end, which is to provide a flat toe seam (10). The layered sock is manufactured complete in a single process being knit continuously from the inner toe end to the outer toe end. It comprises reciprocated heel and toe portions. The foot portion of the inner layer is knit from a yarn with properties such as a low coefficient of friction and/or antifungal/antibacterial properties. The low friction fiber is a fluoropolymer such as polytetrafluoroethylene. The outer layer may comprise a cushion structure. <Figure 3>
Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
Aldonic acid amides of formula (I) and their polyoxyethylenes, polyoxypropylenes, and polyqlycerols are new. HO CH2-(CHOH)m - CONH - R (I) (where m= 2-6; R= straight or branched alkyl of 6-18C). The amides are prepared by reaction of an aldonic acid (II) or the corresponding lactone, HO - CH2 - (CHOH)mCOOH (II) with an amine RNH2, optionally followed by reaction with ethylene oxide, propylene oxide, or glucidol, in then presence of a catalyst. Surfactants and detergents e.g. for cars, cosmetology, biological and microbiological sciences. They may also be used for the lysis of cell membranes and viral capids, solubilisation of proteins, preparation of vaccines, etc. Neutral, stable over a large range of pH and temp., resistant to oxidn, transparent to visible light and near U.V. radiation, high diffusibility, non-irritant to skin and mucous membranes, they are only slight foaming agents and are rapidly biodegradable.
Use of a recombinant vector contg. \-1 promoter, a nucleic acid sequence (I) encoding a desired protein (II) (including a signal sequence) and a 3'-polyadenylation sequence for transfecting kidney cells in an animal (partic. a mammal) is new. (II) is expressed in these cells and produced in the blood or urine of the animal. Also new are:(a) a procedure for the prodn. of a heterologous protein in the urine of a mammal comprising:(i) manufacturing a compsn. contg. the vector as above;(ii) placing the compsn. in contact with kidney tubule cells via the renal artery, the ureter or the pyelocaliceal cavity;(iii) the recovery of the urine via a metabolic casing, and(iv) the opt. purification of (II);(b) medication contg. the vector as above, which can be administered to the renal cells of the host;(c) (II) or polypeptides produced in the blood or urine by the transfected cells;(d) non-human animals contg. renal tubule cells carrying the vector;(e) urine contg. (II) produced by these animals;(f) mammalian renal tubule cells contg. the vector, and(g) antibodies (Ab) (monoclonal or polyclonal) directed against an immunogen (IIa) secreted into the circulation by transformed renal cells.